Clonal tumors develop from a single cancer cell and thus share markers, some of which may be targetable and either highly or even completely conserved.
Cancer puts the immune system into either a somnolent state or a succoring state that is otherwise somnolent.
How can one rouse a person’s immune system against a conserved marker? There are always multiple paths. How about amplifying populations of cells against that marker outside a person’s body and re-injecting the amplified cells?
Here is a leading reference to a workable approach:
Dec. 8, 2016
A woman with metastatic colon cancer is, for now, free of disease after her immune cells were carefully selected to target a gene mutation buried in her tumors, The New York Times reports. As reported today in The New England Journal of Medicine, the 50-year-old engineer and mother of five is the first to benefit from such a therapy, and it’s generating excitement—in part because the mutation, KRAS, is extremely common in certain cancers, has been highly resistant to drugs, and often tracks with a poor prognosis. The woman was treated in a clinical trial at the National Cancer Institute in Bethesda, Maryland, by a team led by Steven Rosenberg, who pioneered use of these immune cells, tumor-infiltrating lymphocytes, against cancer back in the 1990s.